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Over the last 30 years Cochrane has strived to advance the
importance of conducting systematic reviews of therapeutic
strategies, diagnostic tests, and risk factors. Now, the Cochrane
community embarks on systematic reviews of prognosis studies in
the Cochrane Database of Systematic Reviews.
Prognosis research has escalated in the last two decades. Today,
frequently echoed terms are ‘personalized medicine’, ‘precision
medicine’, or ‘risk-based medicine’, often used as synonyms. Almost
all healthcare research programmes, medical journals, and even
private companies (such as Google, IBM, and Philips) adopt these
terms, across all medical domains and settings. Personalized or
precision medicine does not just address effectiveness of
treatments or preventive strategies, but rather addresses how to
use an individual’s prognostic information to make personally
tailored choices about the best suited treatment or preventive
management. Likely due to this worldwide focus on personalized or
precision medicine, studies on prognostic and predictive factors
(markers) and models have become abundant in the medical
literature. Consequently, Cochrane needs to respond to this and
produce systematic reviews that summarize the huge amount of
data and evidence emerging from these primary prognosis studies,
to enable stakeholders to make appropriate healthcare decisions.
The Prognosis Methods Group (methods.cochrane.org/prognosis),
with funding support from Cochrane (Methods Innovation Fund and
Strategic Methods Fund) and supportive academic institutions, has
dedicated time and resources to the development and testing of
novel methods and tools for the design, conduct, quantitative
synthesis, interpretation, and reporting of systematic reviews of
prognosis studies. This work includes strategies and tools for
defining the review question, the PICOTS (population; index
prognostic factor or model; comparative factor or model; outcomes
to be predicted; timing of the prediction horizon and of the moment
of prognosis; setting), search strategies, data extraction, critical
appraisal, risk of bias assessment, quantitative synthesis,
interpretation, reporting, and grading the certainty of summarized
evidence, which can all be found on the Prognosis Methods Group
website.[1]
For specific implementation within Cochrane the Prognosis
Methods Group has developed review proposal and protocol writing
templates, which provide detailed guidance.[2] Review templates
will follow soon. All the Group’s methods and tools will support
systematic reviews of the four main types of prognosis research:
[3][4][5][6]
1. Overall prognosis: studies aimed at quantifying the (overall)
incidence of certain outcomes (e.g. comorbidity, complication,
death, quality of life), occurring in a certain time period (hours, days,
weeks, months, years, lifetime) in individuals within a certain health
state (e.g. diagnosed with a certain disease, undergoing some type
of surgery, being pregnant, or simply being a healthy citizen in the
general population).
2. Prognostic factors: studies aimed at investigating which factors
predict (the occurrence of) certain outcomes occurring in a certain
time period in individuals within a certain health state. Ideally, these
studies address the independent prognostic ability of a factor, i.e.
(multivariably) adjusted for other prognostic factors, rather than the
univariable association of a prognostic factor.
3. Prognostic models: studies aimed at developing, validating,
and adjusting (e.g. extending) multivariable prognostic models that
includemultiple prognostic factors combined, and are to be used
for making predictions in individuals.
4. Treatment selection factors/models: studies aimed at
investigating which factors or combination of factors (models) are
predictive for the outcome or effects of some treatments and not for
the outcome or effects of other treatments.
The Prognosis Methods Group will develop guidance for the conduct
of systematic reviews for all these four types of prognosis studies. To
date, development of methodological guidance has focusedmostly
on types 2 and 3, althoughmost guidance aimed at these types can
also be applied directly to systematic reviews of types 1 and 4, as we
indicate in the review proposal and protocol templates.[2]
The Group also provides training for Cochrane Review authors and
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editors, including five face-to-face workshops given each year at the
Cochrane Colloquium. These 90-minute workshops cover a general
introduction to reviews of prognosis studies, data extraction, risk of
bias assessment, meta-analysis and interpretation (using both
aggregate and individual participant data), and grading of
summarized review results. In 2018 we ran a half-day pre-
Colloquiumworkshop, which will be extended to a full-day
workshop from 2019 onwards. Advanced face-to-face courses at
several locations provide more comprehensive topics on the
synthesis of systematic reviews of prognosis studies. Finally, there
will be online courses - both introductory and advanced courses -
where all the steps of performing a review can be followed,
anywhere in the world.
Since January 2018, when active implementation of systematic
reviews of prognosis studies started within Cochrane, the Prognosis
Methods Group has workedwith many Cochrane Review Groups and
Networks on 17 Cochrane Reviews of prognosis studies. These
reviews cover a wide range of clinical problems and all four types of
prognosis questions and studies. In September 2018, the first of
these systematic reviews was published.[7] This review, published
by Cochrane Wounds, assesses whether protease activity really is
useful in the prediction of wound healing in people with venous leg
ulcers. Another review, nearing completion by Cochrane Metabolic
and Endocrine Disorders, and funded by the World Health
Organization, determines the average risk to develop type 2
diabetes mellitus over different time horizons for people with
intermediate hyperglycaemia.[8] Both these Cochrane Reviews
address a frequent and large problem in their fields and provide a
summary of all existing evidence. In addition to these two reviews,
as of September 2018, 15 more reviews are underway, eight of them
with already published protocols.
Finally, it is important that the Cochrane community produces
systematic reviews of prognosis studies that address relevant
clinical questions and problems. Therefore, we will shortly
undertake a survey of Cochrane editors to scope and prioritize the
prognosis questions in their domains. This will enable us to
optimally spend time and resources to provide the summarized
evidence on the problems that matter.
We look forward to taking up this challenge and rolling out this new
type of review across Cochrane.
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